Apyx Medical (NASDAQ:APYX) Price Target Raised to $6.00

Apyx Medical (NASDAQ:APYX) had its price target increased by Craig Hallum from $5.00 to $6.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research note on Monday, December 29th. Citizens Jmp raised shares of Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research note on Wednesday, November 12th. Roth Mkm started coverage on shares of Apyx Medical in a report on Monday, December 15th. They set a “buy” rating and a $6.00 target price on the stock. Wall Street Zen raised shares of Apyx Medical to a “hold” rating in a research report on Saturday, November 22nd. Finally, BTIG Research upgraded Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Apyx Medical presently has an average rating of “Moderate Buy” and an average target price of $6.50.

Apyx Medical Stock Performance

NASDAQ APYX opened at $3.63 on Wednesday. The firm has a market capitalization of $151.84 million, a P/E ratio of -13.44 and a beta of 1.61. Apyx Medical has a 1-year low of $0.76 and a 1-year high of $4.50. The company has a debt-to-equity ratio of 2.35, a current ratio of 5.00 and a quick ratio of 3.61. The business’s 50-day simple moving average is $3.75 and its 200-day simple moving average is $3.33.

Apyx Medical (NASDAQ:APYX) last posted its earnings results on Tuesday, March 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 114.95%. The firm had revenue of $19.16 million during the quarter, compared to the consensus estimate of $19.12 million. Equities analysts predict that Apyx Medical will post -0.68 EPS for the current year.

Institutional Trading of Apyx Medical

Several large investors have recently bought and sold shares of the company. Citadel Advisors LLC purchased a new stake in shares of Apyx Medical during the third quarter valued at approximately $28,000. Fisher Asset Management LLC purchased a new position in shares of Apyx Medical in the second quarter valued at $34,000. Caprock Group LLC purchased a new position in shares of Apyx Medical in the third quarter valued at $40,000. Hudson Bay Capital Management LP acquired a new stake in Apyx Medical during the 4th quarter valued at $73,000. Finally, Osaic Holdings Inc. acquired a new stake in Apyx Medical during the 2nd quarter valued at $50,000. Institutional investors and hedge funds own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.